MSH6 and PMS2 mutation positive Australian Lynch syndrome families: novel mutations, cancer risk and age of diagnosis of colorectal cancer
Open Access
- 21 May 2010
- journal article
- research article
- Published by Springer Science and Business Media LLC in Hereditary Cancer in Clinical Practice
- Vol. 8 (1), 5-10
- https://doi.org/10.1186/1897-4287-8-5
Abstract
Approximately 10% of Lynch syndrome families have a mutation in MSH6 and fewer families have a mutation in PMS2. It is assumed that the cancer incidence is the same in families with mutations in MSH6 as in families with mutations in MLH1/MSH2 but that the disease tends to occur later in life, little is known about families with PMS2 mutations. This study reports on our findings on mutation type, cancer risk and age of diagnosis in MSH6 and PMS2 families. A total of 78 participants (from 29 families) with a mutation in MSH6 and 7 participants (from 6 families) with a mutation in PMS2 were included in the current study. A database of de-identified patient information was analysed to extract all relevant information such as mutation type, cancer incidence, age of diagnosis and cancer type in this Lynch syndrome cohort. Cumulative lifetime risk was calculated utilising Kaplan-Meier survival analysis. MSH6 and PMS2 mutations represent 10.3% and 1.9%, respectively, of the pathogenic mutations in our Australian Lynch syndrome families. We identified 26 different MSH6 and 4 different PMS2 mutations in the 35 families studied. We report 15 novel MSH6 and 1 novel PMS2 mutations. The estimated cumulative risk of CRC at age 70 years was 61% (similar in males and females) and 65% for endometrial cancer in MSH6 mutation carriers. The risk of developing CRC is different between males and females at age 50 years, which is 34% for males and 21% for females. Novel MSH6 and PMS2 mutations are being reported and submitted to the current databases for identified Lynch syndrome mutations. Our data provides additional information to add to the genotype-phenotype spectrum for both MSH6 and PMS2 mutations.Keywords
This publication has 46 references indexed in Scilit:
- Risks of Lynch Syndrome Cancers for MSH6 Mutation CarriersJNCI Journal of the National Cancer Institute, 2010
- Cancer risk in MLH1, MSH2 and MSH6 mutation carriers; different risk profiles may influence clinical managementHereditary Cancer in Clinical Practice, 2009
- Mismatch repair defective breast cancer in the hereditary nonpolyposis colorectal cancer syndromeBreast Cancer Research and Treatment, 2009
- The Clinical Phenotype of Lynch Syndrome Due to Germ-Line PMS2 MutationsGastroenterology, 2008
- Recently Identified Colon Cancer Predispositions: MYH and MSH6 MutationsSeminars in Oncology, 2007
- The biochemical basis of microsatellite instability and abnormal immunohistochemistry and clinical behavior in Lynch Syndrome: from bench to bedsideFamilial Cancer, 2007
- Estimating cancer risk in HNPCC by the GRL methodEuropean Journal of Human Genetics, 2007
- The multifaceted mismatch-repair systemNature Reviews Molecular Cell Biology, 2006
- Pathogenesis and clinical management of hereditary non-polyposis colorectal cancerBritish Journal of Surgery, 2002
- Mutation in the DNA mismatch repair gene homologue hMLH 1 is associated with hereditary non-polyposis colon cancerNature, 1994